2-(cyclopentyloxy)pyridine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(cyclopentyloxy)pyridine
• 英文别名: 2-cyclopentyloxypyridine
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: OGWSSCLLENRQNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吡啶-2-磺酰氯 在 bis(1,5-cyclooctadiene)nickel (0) 、 potassium tert-butylate 、 三乙胺 、 1,3-双-(2,6-二异丙基苯基)咪唑鎓氯化物 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 1.0h， 生成 2-(cyclopentyloxy)pyridine
  参考文献：
  名称：

  通过S–O键裂解的过渡金属催化的磺酸盐转化：烷基芳基醚和二芳基醚的合成

  摘要：

  磺酸盐（一种通用的医药中间体）的催化转化通常基于C–O键的裂解。然而，在本文中，我们发现通过过渡金属催化的S–O键断裂，磺酸盐发生了罕见的转变，在镍催化剂的存在下，烷基磺酸盐可以通过分子内脱硫C–O偶联形成芳基烷基醚。同时，芳基磺酸盐的性能相似，得到由钯络合物催化的二芳基醚。这种转变可以容忍各种各样的功能。对照实验表明2-吡啶基对于促进反应是必需的。交叉实验证明，这种转化可能部分地通过分子间途径进行。

  DOI：

  10.1021/acs.orglett.9b02858

文献信息

• New Compounds
  申请人：Besidski Yevgeni

  公开号：US20100286202A1

  公开（公告）日：2010-11-11

  The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  本发明涉及新化合物或其盐、溶剂合物或溶剂盐，其制备方法以及用于制备它们的新中间体，含有这些化合物的制药组合物以及将这些化合物用于治疗的用途。
• AMINOPYRIMIDINES AS KINASE MODULATORS
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP1898917A1

  公开（公告）日：2008-03-19
• US8168668B2
  申请人：——

  公开号：US8168668B2

  公开（公告）日：2012-05-01
• [EN] AMINOPYRIMIDINES AS KINASE MODULATORS<br/>[FR] AMINOPYRIMIDINES COMME MODULATEURS DE KINASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006135719A1

  公开（公告）日：2006-12-21

  [EN] Abstract The invention is directed to aminopyrimidine compounds of Formula I: where R3, B, Z, r and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB . The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
  [FR] La présente invention concerne des composés d'aminopyrimidines de formule I : où R3, B, Z, r et R1 sont tels que définis ici. L'invention décrit l'utilisation de tels composés comme modulateurs de la protéine tyrosine kinase, spécialement des inhibiteurs de FLT3 et/ou de c-kit et/ou de TrkB, l'utilisation de tels composés pour réduire ou inhiber l'activité de la kinase de FLT3 et/ou de c-kit et/ou de TrkB dans une cellule ou un sujet, ainsi que l'utilisation de tels composés pour empêcher ou traiter chez un sujet un trouble de prolifération cellulaire et/ou des troubles reliés à FLT3 et/ou à c-kit et/ou à TrkB. La présente invention vise en outre des compositions pharmaceutiques qui comprennent les composés de la présente invention et des procédés pour traiter des troubles tels que des cancers et autres troubles de prolifération cellulaire.
• [EN] SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS SPIRO COMME ANTAGONISTES DES RÉCEPTEURS NPY-Y5
  申请人：GLAXO GROUP LTD

  公开号：WO2009095377A1

  公开（公告）日：2009-08-06

  The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, (I) wherein R is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; Z1 is H, C1-C4 alkyl or F; Z is CH2, CH(C1-C4 alkyl), C(C1-C4 alkyl)2 or a bond; A is a 6-10 membered aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or -C(=O)-X; or O(CH2)0-1R1; B is hydrogen or is a 5-6 membered heteroaryl, or a 4-6 membered heterocycle, or phenyl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxyl, cyano; A and B being linked via any atom; R1 is -(C1-C4)alkyl(C1-C4)alkoxy; or C3-C8 cycloalkyl; or R1 is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or R1 is a 4-6 membered heterocycle, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; X is OR2 or NR3R4; R2 is C1-C4 alkyl; R3 is hydrogen or together with R4 and the nitrogen form a 5-6 saturated membered ring; R4 is C3-C8 cycloalkyl; processes for their preparation, intermediates used in